Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies

A Prospective, Single-Arm Study Evaluating the Safety and Efficacy of DIT101 in Subjects With Relapsed or Refractory Hematologic Malignancies

This study is a single-arm, open-label clinical trial designed to evaluate the safety and tolerability of DIT101 in adults with relapsed or refractory hematologic malignancies and to explore its potential anti-tumor effects.

DIT101 is an investigational in vivo CAR-T cell therapy administered by intravenous infusion. After administration, it is intended to generate CAR-T cells within the patient's body that can recognize and attack tumor cells. Unlike approved autologous CAR-T therapies, DIT101 does not require collection and ex vivo genetic modification of the participant's own cells.

The study includes a screening period, DIT101 infusion treatment, a post-treatment intensive follow-up period of approximately 6 months, and a long-term follow-up period of up to 2 years, with visits every 3-6 months.

Study Overview

• Status: Not yet recruiting
• Conditions: Relapsed or Refractory Hematologic Malignancies
• Intervention / Treatment: Biological: In Vivo CAR-T Therapy

• Study Type: Interventional
• Enrollment (Estimated): 15
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Rui Feng, MD; Phone Number: +(86)13509312934; Email: fengrui@tcelltech.com
• Study Contact Backup: Name: Xianzhen Chen, MM; Phone Number: +(86)18649725652; Email: chenxianzhen@tcelltech.com

Study Locations

• China
  • Tianjin, China
    • Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults aged 18 to <70 years, any gender.
• Voluntarily provide written informed consent and willing to comply with all study procedures.
• Diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL), or other relapsed/refractory hematologic malignancies as judged by the investigator and confirmed by the collaborating institution.
• Tumor cells confirmed positive for the target antigen by immunophenotyping.
• Bone marrow blast ≥5% at screening and/or presence of extramedullary disease.

• For B-ALL/LBL patients, meets criteria for relapsed/refractory disease, including:

  • Primary refractory after ≥2 cycles of standard chemotherapy or not achieving CR after multiple salvage regimens;
  • Relapse within 12 months after CR or ≥12 months relapse after CR not achieving CR after subsequent standard therapy;
  • Relapse after hematopoietic stem cell transplantation;
  • Relapse after prior CAR-T therapy targeting the same antigen.
• ECOG performance status 0-2.
• Expected survival >3 months.

• Adequate organ function, including:

  • Renal: creatinine clearance >45 mL/min;
  • Hepatic: total bilirubin ≤3×ULN, ALT/AST ≤5×ULN;
  • Coagulation: PT, APTT, or INR ≤1.5×ULN;
  • Cardiac: LVEF ≥50% within 1 month;
  • Pulmonary: SpO₂ ≥92% at rest on room air;
  • Hematologic and immune function considered sufficient to tolerate study treatment.
• Women of childbearing potential must have a negative pregnancy test; women considered not of childbearing potential include those who are postmenopausal for ≥12 months or have undergone surgical sterilization (hysterectomy or bilateral oophorectomy).

Exclusion Criteria:

• Pregnant or breastfeeding women.
• Known hereditary bone marrow failure syndromes (e.g., Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other known marrow failure syndromes).
• Uncontrolled active central nervous system leukemia (CNSL; CNS2 or CNS3).

• Prior anti-cancer therapy before screening, including:

  • Systemic chemotherapy within 1 week;
  • Systemic immunotherapy/targeted therapy (monoclonal antibodies, bispecific antibodies, ADCs, etc.) with last dose <5 half-lives or <4 weeks (whichever is shorter);
  • Donor lymphocyte infusion within 6 weeks;
  • CAR-T therapy or hematopoietic stem cell transplantation within 3 months;
  • Radiotherapy within 4 weeks (unless bone marrow reserve >5% and investigator judges it does not affect eligibility);
  • Persistent clinically significant toxicity from prior therapy not recovered to ≤CTCAE Grade 1 (except alopecia).
• Uncontrolled severe active infection.
• History of significant cardiac disease, including: severe heart failure (NYHA class III-IV), myocardial infarction or PCI/stent within 12 months, unstable angina, QTc >480 ms, or other clinically significant arrhythmia per investigator judgment.
• History of CNS injury, seizure, stroke, or brain hemorrhage requiring treatment within 6 months.

• Active viral infections:

  • HIV antibody positive, syphilis serology positive;
  • HBsAg >10⁶ IU/mL;
  • HCV antibody positive;
  • EBV positive (EBER or copy number above normal).
• Need for long-term systemic corticosteroid therapy during DIT-101 infusion (local or inhaled steroids allowed).
• Active autoimmune disease requiring treatment, immunodeficiency, or use of immunosuppressive therapy.
• Acute or moderate-to-severe chronic graft-versus-host disease (GvHD) within 4 weeks prior to screening.
• Known severe allergy to any component of DIT-101.
• Women of childbearing potential or men unable to use effective contraception during DIT-101 infusion and for 1 year post-infusion; plans for pregnancy within 1 year post-infusion in male or female subjects or their partners.
• Any condition that, in the investigator's opinion, may increase risk or interfere with study outcomes.

• Prior malignancy other than hematologic malignancy, except:

  • Malignancy treated with curative intent and disease-free ≥2 years;
  • Non-melanoma skin cancer adequately treated with no current evidence of disease.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: In Vivo CAR-T Therapy for Relapsed or Refractory Hematologic Malignancies; Participants with relapsed or refractory hematologic malignancies will receive 1-2 intraveneous administrations of in Vivo CAR-T (DIT101).	Biological: In Vivo CAR-T Therapy; Participants will receive 1 intravenous administration of DIT101, according to the study dosing regimen. A second dose at the same dose may be administered to eligible participants who show no response after initial treatment, upon sponsor approval.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety#Incidence and severity of adverse events (AEs)	To evaluate the possible adverse events after DIT101 infusion, including the incidence, and severity of AEs	2 years after completion of the DIT101 infusion or until death, whichever occurs first.
Safety#Incidence of Dose Limiting Toxicity (DLT)	Incidence of dose limiting toxicities (DLTs) within 28 days after the first DIT101 infusion.	28 days after the first DIT101 infusion.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Remission (DOR)	Time from first achievement of Complete Response(CR), Complete Response with incomplete hematologic recovery(CRi) or Partial Response(PR) to disease relapse or death due to leukemia.	2 years after completion of the DIT101 infusion or until death, whichever occurs first.
Event-Free Survival (EFS)	Time from DIT101 infusion to earliest occurrence of any event: death after response, relapse, non-response, or treatment discontinuation due to leukemia- or treatment-related death, adverse events, or new anti-cancer therapy (excluding bridging hematopoietic stem cell transplantation (HSCT).	2 years after completion of the DIT101 infusion or until death, whichever occurs first.
Leukemia-Free Survival (LFS)	Time from first achievement of CR/CRi to disease relapse or death.	2 years after completion of the DIT101 infusion or until death, whichever occurs first.
Proportion of Responding Subjects Receiving HSCT	Percentage of subjects who achieve remission after DIT101 infusion and subsequently undergo hematopoietic stem cell transplantation.	Up to 2 years following the completion of DIT101 infusion.
Overall Survival (OS)	Time from first DIT101 infusion to death from any cause.	Up to 2 years after DIT101 infusion or until death, whichever occurs first.
Maximum Concentration (Cmax) of CAR-T Cells in Peripheral Blood	To evaluate the peak expansion level of CAR-T cells in peripheral blood following DIT101 infusion.	up to 2 years after completion of the DIT101 infusion or until death, whichever occurs first.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Maximum Concentration (Tmax) of CAR-T Cells in Peripheral Blood	To evaluate the time required to reach the maximum concentration of CAR-T cells in peripheral blood following DIT101 infusion.	up to 2 years after completion of the DIT101 infusion or until death, whichever occurs first.
Area Under the Concentration-Time Curve (AUC) of CAR-T Cells in Peripheral Blood	To evaluate the total exposure of CAR-T cells in peripheral blood following DIT101 infusion.	up to 2 years after completion of the DIT101 infusion or until death, whichever occurs first.
Level of Interleukin-6 (IL-6) in Peripheral Blood	To evaluate the concentration levels and changes from baseline of Interleukin-6 (IL-6) in peripheral blood at various time points following DIT101 infusion.	Baseline, specified time points post-infusion, up to 2 years after completion of the DIT101 infusion.
Level of Interleukin-10 (IL-10) in Peripheral Blood	To evaluate the concentration levels and changes from baseline of Interleukin-10 (IL-10) in peripheral blood at various time points following DIT101 infusion.	Baseline, specified time points post-infusion, up to 2 years after completion of the DIT101 infusion.
Level of Interferon-γ (IFN-γ) in Peripheral Blood	To evaluate the concentration levels and changes from baseline of IFN-γ in peripheral blood at various time points following DIT101 infusion.	Up to 2 years after completion of the DIT101 infusion or until death, whichever occurs first.
Level of Tumor Necrosis Factor-α (TNF-α) in Peripheral Blood	To evaluate the concentration levels and changes from baseline of TNF-α in peripheral blood at various time points following DIT101 infusion.	Up to 2 years after completion of the DIT101 infusion or until death, whichever occurs first.

Collaborators and Investigators

• Sponsor: Tcelltech Inc.
• Investigators: Study Chair: Gangxiong Huang, MD, Tcelltech Inc.

Study record dates

Study Major Dates

• Study Start (Estimated): April 15, 2026
• Primary Completion (Estimated): October 15, 2028
• Study Completion (Estimated): October 15, 2028

Study Registration Dates

• First Submitted: March 2, 2026
• First Submitted That Met QC Criteria: March 16, 2026
• First Posted (Actual): March 20, 2026

Study Record Updates

• Last Update Posted (Actual): March 20, 2026
• Last Update Submitted That Met QC Criteria: March 16, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Site; Neoplasms; Disease Attributes; Hematologic Diseases; Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases; Recurrence; Hematologic Neoplasms
• Other Study ID Numbers: DIT101-IBL001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No